

Number 779 • January 2019

Service Alert – Planned POS System Outage

Alberta Blue Cross is completing routing maintenance on our PRIDE-RT system, as such, on January 20, 2019, you may experience a slight delay in availability prior to 9 a.m.

Temporary benefits added to the Alberta Drug Benefit List (ADBL)

Due to the unavailability of Ketorolac Tromethamine 30 mg/ml Injection (DIN 02239944) manufactured by Sandoz Canada Inc., Ketorolac Tromethamine 30 mg/ml Injection (DIN 02244947) manufactured by Fresenius Kabi Canada and Ketorolac Tromethamine 30 mg/ml Injection (DIN 02443376) manufactured by MDA Inc., will be considered as temporary benefits for the *Alberta Drug Benefit List (ADBL)*.

As of **December 22, 2018**, all claims for Ketorolac Tromethamine 30 mg/ml Injection (DIN 02244947) and Ketorolac Tromethamine 30 mg/ml Injection (DIN 02443376) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at <u>ab.bluecross.ca/providers/pharmacy-home.html</u>.

If this situation continues to be a long-term matter then these products are subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics, and must be approved by the Minister of Health for addition to the *ADBL* in order to remain as a benefit.

Due to the unavailability of Acetylcysteine 20% Inhalation Solution (DIN 02243098) manufactured by Sandoz Canada Inc., Acetylcysteine 20% Inhalation Solution USP (DIN 02459906) manufactured by Teligent Canada Inc., will be considered as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

As of January 4, 2019, all claims for Acetylcysteine 20% Inhalation Solution USP (DIN 02459906) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at <u>ab.bluecross.ca/providers/pharmacy-home.html</u>.

If this situation continues to be a long-term matter then these products are subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics, and must be approved by the Minister of Health for addition to the *ADBL* in order to remain as a benefit. Due to the unavailability of pms-Sulfasalazine 500 mg Enteric-Coated Tablet (DIN 00598488) manufactured by Pharmascience Inc., Salazopyrin En-Tabs 500 mg Enteric-Coated Tablet (DIN 02064472) manufactured by Pfizer Canada ULC, will be considered as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

As of January 14, 2019, all claims for Salazopyrin En-Tabs 500 mg Enteric-Coated Tablet (DIN 02064472) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at <u>ab.bluecross.ca/providers/pharmacy-home.html</u>.

If this situation continues to be a long-term matter then these products are subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics, and must be approved by the Minister of Health for addition to the *ADBL* in order to remain as a benefit.

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free) **FAX 780-498-8406** (Edmonton and area) • **FAX 1-877-305-9911** (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims. **Visit ab.bluecross.ca/providers/pharmacy-home.php**



**The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. *† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. ABC 82320.779 2019/01

